Since mutant p53 (mutp53) reshapes the tumor microenvironment (TME) [12, 17], a promising approach may be to define the mutp53-driven secretome, the collection of factors secreted by tumor cells harboring mutp53, as a mean to identify new druggable targets that enhance cancer progression, immune evasion, drugs resistance and metastasis [18, 19]. Here, TP53 is linked to cancer.